Showing posts with label outcomes. Show all posts
Showing posts with label outcomes. Show all posts

Wednesday, July 15, 2026

Shoulder arthritis and shoulder arthroplasty - what's new (if anything)

Two articles in the recent JSES are of note.

Advanced glenohumeral osteoarthritis: the relationship between radiographic pathoanatomy and clinical presentation asks "does the x-ray tell us how the patient is doing?" The authors studied 280 shoulders with advanced glenohumeral osteoarthritis and an intact cuff, all of which went on to arthroplasty: 147 anatomic total shoulders, 81 reverses, and 52 ream and runs [1]. Every shoulder was graded before surgery by three classifications: Samilson-Prieto, Kellgren-Lawrence, and the Walch system as modified for three-dimensional imaging [3,4,5]. The authors also measured critical shoulder angle, humeral head medialization, humeral head flattening, the length of the inferior humeral neck spur, posterior decentering, glenoid version, and glenoid inclination. Then they asked whether any of these predicted how the shoulder moved, how comfortable it was, or how the patient rated his or her health.

With two exceptions, it did not. No clinically meaningful association between Samilson-Prieto grade, Kellgren-Lawrence grade, Walch type, critical shoulder angle, medialization, version, or inclination and any patient-reported outcome or quality-of-life score. The exceptions were both on the humeral side: greater flattening of the head and a longer humeral neck spur were associated with less motion.

This replicates what we reported in 2019 in 544 shoulders [6], what Kohan and colleagues reported in 256 [7], and what Kircher and colleagues reported earlier still [13]. Four groups, four cohorts, one answer: the radiographic severity of the arthritis does not tell us what the patient is experiencing.

The second paper ---Reverse and anatomic total shoulder arthroplasty for glenohumeral osteoarthritis: a propensity-matched comparison at early and midterm follow-up ‚--- asks "does the implant choice change the result?" From a single high-volume surgeon's practice, Leinweber and colleagues matched 61 anatomic total shoulders to 61 reverses, one to one, on age, sex, body mass index, preoperative ASES, preoperative forward elevation, and Walch glenoid type [2]. Notably, they matched on the very pathoanatomy that the first paper found does not predict much. All shoulders had osteoarthritis with an intact cuff. All were seen early (about two years) and at midterm (about five years).

Both groups improved a great deal, and by the same amount. More than 96% of patients in both groups reached the minimal clinically important difference for the ASES at both time points. The anatomic patients had better external rotation at the early visit (63 degrees vs. 57 degrees) and better internal rotation as well; by five years the internal rotation advantage was gone and the external rotation difference had narrowed. Complications were 3.3% in each group.

Putting these papers side by side

Consider what each study holds constant and what it lets vary.

The second paper holds the surgeon constant and varies the implant. It finds no meaningful difference in what the patient reports.

The first paper considers the variable pathoanatomy across 280 shoulders and finds that it explains almost nothing about how the patient presents.

Neither the glenoid nor the prosthesis seems to matter. (The two measures that did survive are on the humerus, and we will come to them a bit later.) If the explanation for the differences among our patients' outcomes is not in the glenoid we spend our time classifying and not in the implant we spend our time choosing, the two possibilities left standing are the patient and the surgeon.

One incidental note: the two papers used different MCID values for the same score ‚--- 16 points for the ASES in the first [8], 10.4 points in the second [9]. Both are defensible and both are published. Whether a result is "clinically important" can depend on which threshold the authors selected.


A closer look at the first paper

Eight radiographic parameters and six classification terms were each tested against eleven outcomes: 154 comparisons, with no correction for multiplicity. At the conventional threshold, roughly eight false positives are expected by chance alone. Seventeen associations were reported as significant ‚ --- more than chance alone would produce. Of those seventeen, the authors' own MCID screen disqualified nearly every one. The findings are not false; they are true but too small to act on.

Four associations survived as "clinically relevant":

Forward elevation and humeral head flattening. A coefficient of 0.56 degrees per percentage point of humeral head flattening, against an MCID of 17.1 degrees [8], requires a change in flattening of about 30 percentage points: nearly five standard deviations, and roughly three-quarters of the entire observed range.

External rotation and head flattening. About 24 percentage points, close to four standard deviations.

Neither is a quantity that could exist in a patient.

Internal rotation and head flattening. About 10 percentage points, 1.6 standard deviations, entirely attainable.

External rotation and humeral neck spur. A difference in spur length of about 22 mm, well within the observed range of 0 to 48 mm. This result replicates Kircher [13].

Those last two are real, they are reachable, and they are both on the humeral side ‚ ---where nobody has been looking ‚ --- rather than on the glenoid, where everyone has been looking. In other words the strongest signals in 280 shoulders are from the humerus;  the glenoid---the object of twenty years of classification---apparently contributes little.

A limitation of the analysis is that every shoulder in this series went on to arthroplasty. That is a range-restricted sample: each of these patients had already crossed somebody's operative threshold, so the variance in symptoms is truncated at the low end, and truncation attenuates correlation. Some of the null result is built into the sampling. The claim is not "radiographs never relate to symptoms." The actual finding is: among patients already being considered for shoulder arthroplasty, the images doe not tell you who hurts, how much, or how far the shoulder moves.

In the subgroup analysis, the concentric (Walch A) glenoids had worse pain, worse DASH, and worse ASES than the eccentric (Walch B) glenoids. By the standard we have just applied to the rest of the paper, these differences fall below the MCID and we should not make much of them‚---so we will only state: the direction runs opposite to the expectation of most surgeons. The eccentric, retroverted, posteriorly decentered glenoid is the one that most often prompts a surgeon from an anatomic reconstruction to a reverse. In this cohort those shoulders were, if anything, the more comfortable ones. That is not what much current thinking about the B glenoid would predict, and it is worth a study designed to test it rather than a subgroup that happened to find it.



A closer look at the second paper

The surgeon performed 1,310 reverses and 546 anatomic total shoulders in the study window. Of the reverses, 133 (only 10% of the original cohort) had complete clinical and outcome follow-up at both time points; 61 entered the matched analysis. Of the anatomics, 129 (only 24% of the original cohort) qualified; 61 entered the matched analysis. So the survivorship bias and the matching dramatically reduced the studied sample size, making it less relevant to the original group of patients.

Note the inclusion rule was complete outcome scores and clinical follow-up at both visits. That rule removes the patients who were revised elsewhere, who stopped answering, who were dissatisfied and did not come back, and who died. The paper then reports a 0% revision rate for the reverse and a 1.6% acromial stress fracture rate. These are not accurate incidence estimates. A revision rate cannot be calculated in a cohort whose definition requires having completed follow-up; it requires the whole exposed group and a time-to-event analysis.

Substantial clinical benefit was reached by 95.1% of anatomic patients and 80.3% of reverse patients early. That 14.8-point gap has a P value of .027 and is discussed as a real difference. At five years the gap was 13.1 points (91.8% vs. 78.7%), with a P value of .074, and was described as no significant difference.

The two gaps are nearly the same size. What changed is which side of .05 the P value fell on, in a study that states it could not perform a power analysis. A 13-point difference in substantial clinical benefit at five years has not been shown to be absent; it has merely not been shown to be present. Those are different statements, and only the second one is supported here. The gap favors the anatomic shoulder at both time points, and it deserves a larger study rather than a rounding to "similar."

When more than 96% of both groups clear the MCID, the MCID has stopped discriminating. It tells us that both operations work, which is worth knowing and is the correct headline. It cannot tell us whether they work equally well.

Revision is not a good metric

One anatomic shoulder was revised; no reverse was. That appears in the abstract as "aTSA had more revisions." A failed anatomic shoulder has somewhere to go, --- conversion to a reverse. A failed reverse does not, and the threshold for taking a painful reverse back to the operating room is far higher, because the surgeon has less to offer. A revision count compares the availability of a salvage operation as much as it compares the durability of an implant. Counting one against zero and reporting it as a durability signal asks a single patient to carry the argument.

The same asymmetry appears in how radiographic failure was judged. A reverse with baseplate lucencies and broken screws was recorded as a non-failure because the patient was comfortable. Asymptomatic glenoid lucencies after anatomic arthroplasty, graded by the Lazarus system [10], were simultaneously presented as the durability liability. One standard should apply to both.

The whole argument for using a reverse in a cuff-intact arthritic shoulder is long-term durability: glenoid loosening and late cuff failure at ten, fifteen, twenty years. Five years samples precisely the window in which the anatomic shoulder is known to do well [11], and the one series that has followed eccentric-wear shoulders past that window to a minimum of seven years found the anatomic reconstruction holding up [12]. This study cannot address the question that prompted it.

The variable neither study measured

Put the two preoperative cohorts next to each other. Both are advanced osteoarthritis with an intact cuff, in the same country, in the same era. The shoulders moved almost identically before surgery: mean forward elevation 96.6 degrees in the first series, 97.5 degrees and 98.2 degrees in the second.

The patients, however, were not in the same condition. Mean preoperative ASES was 29.9 in the first series and 41.4 and 38.9 in the second. Mean pain was 7.4 out of 10 versus 5.3 and 5.5. The patients in one practice arrived at the operating room roughly ten ASES points and two pain points better off than the patients in the other.

There is more than one way to get such a gap. These are different practices with different referral streams, different payer mixes, and different geography; the first cohort also includes 52 ream-and-runs, a self-selected group that has no counterpart in the second practice. So the difference may reflect who walks through the door as much as when the surgeon decides to operate. But that distinction does not rescue the number. Referral pattern and operative threshold are both properties of the practice, not of the shoulder. Either way, what varies between these two cohorts is the surgeon's context, not the patient's pathoanatomy ‚ --- and it varies by more than the pathoanatomy does. This is the kind of unwanted variation that Kahneman called noise.

What this may mean

If you are a patient looking at your own x-ray or CT scan, the first paper is reassuring: the severity of what you see on the film does not predict how much your shoulder will hurt, how far it will move, or how you will feel about your life. Some very ugly-looking shoulders belong to comfortable people, and some mild-looking ones hurt badly. The x-ray describes the joint. It does not describe you.

If you are a patient choosing between an anatomic and a reverse replacement for arthritis with an intact cuff, the second paper says that at five years, in the hands of one experienced surgeon, both do well. The anatomic shoulders showed somewhat better rotation early, though by the standard applied above that early difference is at the edge of what a patient would notice. What happens after five years is not yet known, and that is the question that actually separates these two operations.

If you are a surgeon, the two papers together take away two of the things you were counting on. The images you spend the most time studying did not explain how the patient presented. The implant you spent the most time deciding on did not explain how the patient ended up. What is left is the judgment that sits between them: whom you offer an operation to, when in the course of the disease you offer it, what you tell the patient to expect, and how well you execute. Those are the variables neither study measured, and the ten-point preoperative ASES gap between these two practices is a direct measurement of how much they vary from one surgeon to the next.

We keep looking for the explanation in the imaging and in the implant because those are the things we can see and buy. The evidence keeps pointing somewhere else.

Both of these are careful papers by serious groups, and both are more honest in their limitations sections than most. The first calls itself a pilot and names its multiplicity problem. The second calls itself hypothesis-generating, names the risk of type II error, and says that longer follow-up is needed. 

The larger point stands. 

Twenty years of classifying the glenoid has not produced a classification that predicts what the patient feels. 

Ten years of moving the reverse into the cuff-intact arthritic shoulder has not yet produced evidence that it does better than the anatomic shoulder we already had. 

The trial that could settle it would randomize, follow to fifteen years, and report substantial clinical benefit rather than the MCID.

Which leaves the question: if the picture does not explain the patient's presentation and the implant does not explain the result, what does?



Where are we going?
Snow Geese
Skagit County




[1] Covarrubias O, Luther L, Portnoff B, Levins J, Hoffman R, Molla V, Toavs T, Molino J, Paxton ES, Green A. Advanced glenohumeral osteoarthritis: the relationship between radiographic pathoanatomy and clinical presentation. J Shoulder Elbow Surg 2026;35:1620-1631. https://doi.org/10.1016/j.jse.2026.01.007

[2] Leinweber KA, Bowler AR, Diestel DR, McDonald-Stahl M, Arnold RP, Le K, Dunn WR, Kirsch JM, Jawa A. Reverse and anatomic total shoulder arthroplasty for glenohumeral osteoarthritis: a propensity-matched comparison at early and midterm follow-up. J Shoulder Elbow Surg 2026;35:1632-1641. https://doi.org/10.1016/j.jse.2025.12.008

[3] Samilson RL, Prieto V. Dislocation arthropathy of the shoulder. J Bone Joint Surg Am 1983;65:456-460.

[4] Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.

[5] Bercik MJ, Kruse K 2nd, Yalizis M, Gauci MO, Chaoui J, Walch G. A modification to the Walch classification of the glenoid in primary glenohumeral osteoarthritis using three-dimensional imaging. J Shoulder Elbow Surg 2016;25:1601-1606. https://doi.org/10.1016/j.jse.2016.03.010

[6] Matsen FA 3rd, Whitson A, Hsu JE, Stankovic NK, Neradilek MB, Somerson JS. Prearthroplasty glenohumeral pathoanatomy and its relationship to patient's sex, age, diagnosis, and self-assessed shoulder comfort and function. J Shoulder Elbow Surg 2019;28:2290-2300. https://doi.org/10.1016/j.jse.2019.04.043

[7] Kohan EM, Hill JR, Lamplot JD, Aleem AW, Keener JD, Chamberlain AM. Severity of glenohumeral osteoarthritis does not correlate with patient-reported outcomes. J Shoulder Elb Arthroplast 2020;4:2471549220901873. https://doi.org/10.1177/2471549220901873

[8] Simovitch RW, Elwell J, Colasanti CA, Hao KA, Friedman RJ, Flurin P, et al. Stratification of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after total shoulder arthroplasty by implant type, preoperative diagnosis, and sex. J Shoulder Elbow Surg 2024;33:e492-e506. https://doi.org/10.1016/j.jse.2024.01.040

[9] Levy JC, Everding NG, Gil CC Jr, Stephens S, Giveans MR. Speed of recovery after shoulder arthroplasty: a comparison of reverse and anatomic total shoulder arthroplasty. J Shoulder Elbow Surg 2014;23:1872-1881. https://doi.org/10.1016/j.jse.2014.04.014

[10] Lazarus MD, Jensen KL, Southworth C, Matsen FA 3rd. The radiographic evaluation of keeled and pegged glenoid component insertion. J Bone Joint Surg Am 2002;84:1174-1182. https://doi.org/10.2106/00004623-200207000-00013

[11] Kirsch JM, Puzzitiello RN, Swanson D, Le K, Hart PA, Churchill R, et al. Outcomes after anatomic and reverse shoulder arthroplasty for the treatment of glenohumeral osteoarthritis: a propensity score-matched analysis. J Bone Joint Surg Am 2022;104:1362-1369. https://doi.org/10.2106/JBJS.21.00982

[12] Cuff DJ, Simon P, Patel JS, Munassi SD. Anatomic shoulder arthroplasty with high side reaming versus reverse shoulder arthroplasty for eccentric glenoid wear patterns with an intact rotator cuff: comparing early versus midterm outcomes with minimum 7 years of follow-up. J Shoulder Elbow Surg 2023;32:972-979. https://doi.org/10.1016/j.jse.2022.10.017

[13] Kircher J, Morhard M, Magosch P, Ebinger N, Lichtenberg S, Habermeyer P. How much are radiological parameters related to clinical symptoms and function in osteoarthritis of the shoulder? Int Orthop 2010;34:677-681. https://doi.org/10.1007/s00264-009-0846-6
 

Monday, June 1, 2026

Pyrocarbon in the Shoulder: what we think we know. Section 2

As a sequel to the prior post (Section 1), here is a look at the literature on clinical results for the pyrocarbon shoulder implants. Results can be expressed as (a) revision rate and (b) patient-reported outcomes (PRO). At the outset we recognize that lack of a revision is not the same as a clinically significant improvement (i.e., improvement in PRO that exceeds the minimal clinically important difference, MCID). Lack of a revision may result from patient unwillingness to undergo another procedure, patient lost to follow-up, poor patient health, or patient death — none of which indicate a clinically significant improvement.

An issue confounding the available clinical results for pyrocarbon implants is that reports often combine legacy devices, revised versions, and current instantiations.


PYRO TYPE 1: PROXIMAL HUMERAL RESURFACING (PHR/PYROTITAN)

This implant has been through at least three significant design iterations and three commercial sponsors. None of the published papers isolates the current implant configuration. Every survivorship figure in the literature pools generations. The lineage, reconstructed from the McBride 2026 paper [1], the Hoy 2026 paper [2], the Therapeutic Goods Administration hazard alert [3], and contemporaneous trade press, is summarized in the following table.


The McBride 2026 registry cohort (n = 403, enrolled 2004–2022) spans all three iterations; and the reported 35%-of-revisions-from-breakage figure averages performance across known-fracture-prone implants and the current design.[1] The Hoy 2026 cohort (n = 119, enrolled January 2013–November 2023) starts at about the time of the TGA hazard alert; the earliest patients received the first-redesign implant; mid-cohort patients received the second-redesign implant, and late patients received the current implant.[2] Thus, the result for the current commercially available PHR/PyroTITAN implant is unknown. It cannot be extracted from the existing literature because every published series pools at least two device generations.

Here is what relates to the post-2017 third design:

Survivorship:  cumulative percent revision (CPR) 7.7% at 10 yr (McBride 2026 [1]); 5-year Kaplan–Meier survivorship 97.5% (mean follow-up 34.6 months) (Hoy 2026 [2]). Manufacturer filings (not peer-reviewed): Kaplan–Meier survival ~86% up to ~117 mo as posted to ClinicalTrials.gov (NCT02405208 [9]). The primary endpoint of NCT02983292 [8] is device survival, not patient-reported outcomes; results are not yet published.

Effectiveness:  WOOS 38→83 and ASES 49→87, all exceeding MCID (Hoy 2026 [2]).


PYRO TYPE 2: THE U.S. STEMMED PYROCARBON HEMIARTHROPLASTY (HA-PYC)

The FDA Investigational Device Exemption study [4] enrolled patients between December 2015 and April 2017, before the final round of design changes. The De Novo clearance was granted in 2022, and U.S. commercial use of the pyrocarbon humeral head began only in March 2023. The Griswold 2025 JBJS paper [5] reports the IDE patients at 5 years, not the post-clearance commercial cohort.

Survivorship:  3 of 157 revised before 24 mo, mean follow-up 24.4 mo; 3-year Kaplan–Meier revision-free survival 96.6% (Hatzidakis 2026 [4]). In the same IDE lineage followed forward (n = 45, mean follow-up 73 mo), 7-year revision-free survival 95.7% and failure-free survival 93.4% — the 2 revisions were both for infection (Griswold 2025 [5]).

Effectiveness:  Composite Clinical Success 82.7%, defined as a ≥17-point Constant-score improvement without revision or device-related adverse event; ASES 44→88, adjusted Constant 51→91, SANE 36→85 (Hatzidakis 2026 [4]). At ≥5 years (mean 73 mo): ASES 47→96, SANE 39→94, Constant 48→88, all exceeding MCID, with glenoid morphology stable between the 2-year and final imaging (Griswold 2025 [5]).


PYRO TYPE 3: THE EUROPEAN STEMMED PYROCARBON HEMIARTHROPLASTY

The European cohort, followed a mean of 5.6 years [6], pools shoulders implanted before and after the systematic head-downsizing maneuver that became standard once Cointat reported that nonanatomic reconstruction (center of rotation > 3 mm off the anatomic center) occurred in 29% of cases and was strongly associated with glenoid erosion and revision [7].

With the current downsizing technique (Boileau 2026 [6]):

Survivorship:  revision-free survival 94% at 5 yr and 89% at 10 yr.

Effectiveness:  Constant 29→77, SSV 25%→84%, 91% return to work, 88% return to sport.


SUMMARY

Pyrocarbon shoulder arthroplasty is an exciting technology that is rapidly evolving. While evolution to address clinical issues (fracture, overstuffing, component malposition) is critical, it does confound the study of clinical outcomes: the implants on which follow-up data are available are often not the ones in current use. Once the designs and techniques have stabilized, data on revision rates and patient-reported outcomes for them will be of great interest.


Black vulture
San Antonio
2025


Follow on twitter/X: https://x.com/RickMatsen
Follow on facebook: https://www.facebook.com/shoulder.arthritis
Follow on LinkedIn: https://www.linkedin.com/in/rick-matsen-88b1a8133/


REFERENCES

1. McBride A, Hurley R, Gill D, Du P, Duke P, Taylor F, Hoy G, Page R, Ross M. Outcomes of pyrolytic carbon humeral resurfacing hemiarthroplasty compared to best-in-class total shoulder arthroplasty in young patients with osteoarthritis: analysis from the Australian Orthopaedic Association National Joint Replacement Registry. J Shoulder Elbow Surg. 2026;35(5):1209–1218. doi:10.1016/j.jse.2025.09.007.


2. Hoy G, Burrows K, McBride A, Ross M, Davis K, Warby S. PyroTITAN Pyrocarbon Shoulder Hemiarthroplasty: Clinical and Radiographic Outcomes with Medium-Term Follow-up. J Bone Joint Surg Am. Epub 2026 May 13. doi:10.2106/JBJS.25.00779.


3. Therapeutic Goods Administration. PyroTitan humeral resurfacing arthroplasty — hazard alert. Canberra, Australia: Australian Government Department of Health; August 2013. Available at: https://www.tga.gov.au/safety/recalls-and-other-market-actions/market-actions/pyrotitan-humeral-resurfacing-arthroplasty (LMT Surgical, 3% worldwide implant breakage rate, sub-surface fractures identified).


4. Hatzidakis AM, Garrigues GE, Mauter LA, de Gast A, Venegoni MR, Yang Y, Johnston PS. Clinical Outcomes of Pyrocarbon Hemiarthroplasty: A Short-Term, Multicenter Study. J Bone Joint Surg Am. 2026;108(8):572–583. doi:10.2106/JBJS.25.00054.


5. Griswold BG, Berger JM, Davis BP, Mauter L, Boyd M, Schuette HB, Johnston PS, Sears BW, Hatzidakis AM. Five-Year Radiographic and Clinical Outcomes of Pyrocarbon Hemiarthroplasty for Glenohumeral Arthritis and Osteonecrosis. J Bone Joint Surg Am. 2025;107(24):2751–2762. doi:10.2106/JBJS.25.00163.


6. Boileau P, Cointat C, Raynier JL, Schippers P, Ranieri R. Pyrocarbon hemiarthroplasty for the treatment of shoulder osteoarthritis in young, active patients: survival and risk factors for revision. J Shoulder Elbow Surg. 2026;35(2):421–437. doi:10.1016/j.jse.2025.06.021.


7. Cointat C, Raynier JL, Vasseur H, Lareyre F, Raffort J, Gauci MO, Boileau P. Short-term outcomes and survival of pyrocarbon hemiarthroplasty in the young arthritic shoulder. J Shoulder Elbow Surg. 2022;31(1):113–122. doi:10.1016/j.jse.2021.06.002.


8. ClinicalTrials.gov. A Clinical and Radiological Study to Evaluate the Safety and Efficacy of the PyroTITAN Humeral Resurfacing Arthroplasty (HRA) Device in a New Cohort of Patients After Product Re-Release (T-HRA-003). NCT02983292. Sponsor: Smith & Nephew. Completed February 2023; results posted to ClinicalTrials.gov 2024 (not peer-reviewed). https://clinicaltrials.gov/study/NCT02983292.


9. ClinicalTrials.gov. A Multi-center Outcomes Clinical Study of the PyroTITAN HRA Shoulder Implant in Humeral Head Resurfacing (CP-HRA-002). NCT02405208. Sponsor: Smith & Nephew. Enrollment 156; completed September 2023; results posted to ClinicalTrials.gov 2025 (not peer-reviewed). https://clinicaltrials.gov/study/NCT02405208.

Saturday, March 21, 2026

CoCr Ream and Run - comparison to aTSA, how much wear, how much does it matter, satisfaction


The ream and run (RnR) is a glenohumeral arthroplasty in which the arthritic humeral head is replaced with a chrome-cobalt humeral head similar to that used in conventional total shoulder arthroplasty. The key difference is that rather than implanting a plastic glenoid component, the glenoid bone is conservatively reamed to a concentric concavity and allowed to remodel during the rehabilitation period. This procedure eliminates the limitations and risks of loosening associated with a plastic glenoid component.


Four recent papers contribute to our understanding of the Ream and Run. Note that none of the authors have a financial conflict of interest with the companies making the implants used in these studies.

Brad Carofino, former University of Washington Shoulder Fellow, working in Virginia Beach has provided the most rigorous data on the ream and run to come from a center outside Seattle. Here are two of his recent publications

Paper #1 Comparison of short- and midterm outcomes inpatients following ream-and-run and anatomic total shoulder arthroplasties   J. Shoulder Elbow Surg (2025) 34, 794-802. A matched  cohort study compared ream and run (RnR) outcomes to anatomic total shoulder arthroplasty (aTSA).  The RnR procedures were all performed by an individual surgeon. A multicenter database was used to provide the matched cohort of patients who underwent the aTSA procedure. Only male patients were included; average age was 56 years. 

Of note this surgeon accepts 2 - 8 mm of diametral mismatch between the humeral head and the reamed glenoid when performing the RnR, selecting the reamer size that removes the least amount of bone without attempting to change preoperative glenoid version. When selecting the humeral head implant size, he selected a head diameter to approximate the patient’s anatomy; 54- and 56- mm-diameter heads were the most used sizes. For head height, the surgeon favored the thinnest option for that diameter (15 or 18 mm). Because patients are encouraged to obtain 160 degrees of passive forward elevation within the first few days, range of motion exercises are started the day of surgery and performed 3-5 times per day for the first 6 weeks.

The Simple Shoulder Test and ASES scores for RnR were not inferior to those for aTSA at a mean three-year follow-up; revision rates and satisfaction were essentially the same.  

 
RnR outcomes were not different between patients with preoperative type A and type B glenoids. 


Preoperative humeral decentering was corrected (50% indicates that the humeral head is centered on the glenoid).


Paper #2. Patient self-selection does not influence postoperative improvements in pain, function, or satisfaction in ream-and-run arthroplasty patients  Shoulder Elbow Surg. 2026 Apr;35(4):989-994.  determined whether patients who specifically seek out the RnR are representative of the general shoulder arthritis population.  The authors compared two groups from their practice: self-selectors (patients who specifically sought the ream and run) and walk-in candidates (patients who were offered the procedure by their surgeon and accepted, without having sought it out). 

Patients self-selecting the RnR arthroplasty reported pain and functional improvements as well as satisfaction ratings similar to those who were not specifically seeking out the procedure. Both groups achieved approximately 84–88% of maximum possible improvement on the SST and approximately 78% on the ASES. More than 93% of patients in both groups reached the minimal clinically important difference.


Two papers came from the University of Washington Shoulder Team.

Paper #3 Which shoulder functions correlate with patient satisfaction after primary shoulder arthroplasty?  J Shoulder Elbow Surg. 2026 Jan;35(1):19-27. The ability to sleep comfortably, to perform overhead function and to toss a softball were most predictive of satisfaction. 

Paper #4 Characterizing glenoid wear after hemiarthroplasty with concentric glenoid reaming: a study of 113 arthroplasties at a mean of 6.7 years of follow-up J Shoulder Elbow Surg. 2026 Apr;35(4):995-1002. assessed medial migration of the humeral head and its relation to clinical outcome. Glenoid wear was quantified by measuring the position of the humeral head center of rotation relative to a line passing through the lateral tip of the acromion and parallel with the superior and inferior margins of the glenoid articular surface (below on the left: the immediate postoperative film, on the right: the five year postoperative film) 




Medialization occurred predominantly in the first two years as the reamed glenoid adapted to load and tended to level off thereafter. The characteristic amount of medialization at 10 years was 3.5 mm.




Of importance is the observation that medialization did not correlate with outcome: patients with greater medialization achieved SST and ASES scores equivalent to those with less wear. Overall satisfaction exceeded 97%. Twelve shoulders were revised for stiffness or malposition, eight of these were revised to a repeat RnR, one to aTSA, one to RSA, one to CTA hemiarthroplasty, and one was a soft tissue release.

Conclusion: These studies and the preceding literature suggest that RnR with a chrome-cobalt humeral head and conservative reaming without version correction delivers consistent, durable results across follow-up durations, across glenoid morphologies, across surgeons, and across patient selection pathways. 

These studies provide data to which alternative approaches, such as pyrocarbon and ceramic heads can be compared.

For younger, active patients with cuff-intact glenohumeral arthritis who wish to avoid the risk of glenoid component loosening, the ream and run merits consideration as a first-line operative treatment. 

Here's an example of an active, athletic man who had bilateral RnRs. The right 18 years ago and the left 11 years ago. The x-rays below show the preop and current x-rays of each shoulder. He has been able to return to essentially full activity with each.


He kindly gave permission to show the videos of his shoulder motion that I took recently. 



This outcome shows what a motivated patient can accomplish after a RnR.

For younger, active patients with cuff-intact glenohumeral arthritis who wish to avoid the risk of glenoid component loosening, the ream and run merits consideration as a first-line operative treatment. 


Under development
Barred owl chick
Washington Park Arboretum 2024


Follow on twitter/X: https://x.com/RickMatsen

Follow on facebook: https://www.facebook.com/shoulder.arthritis

Follow on LinkedIn: https://www.linkedin.com/in/rickmatsenmd

Thursday, March 5, 2026

Complications and revisions following reverse total shoulder: doing the math.


Summary: Three takeaway points

(1) The commonly used and easy to measure "revision rate" is an inadequate endpoint for evaluating rTSA outcomes. The 8–20 percentage point gap that exists between the complication rate and the revision rate includes a substantial number of patients with failed but unrevised reverse shoulder arthroplasties. These patients are not considered in determining the failure rate when measured by the percentage having revision. Complication-free survival or patient-reported outcome measures should supplement or replace revision rate or "implant survival" as the primary outcome measure for rTSA.

(2) The most common complications of rTSA, acromial and scapular spine fractures, are unique and difficult to solve problems for patients having reverse arthroplasty. In contrast, the most common complications from aTSA - glenoid component loosening and rotator cuff tear - can be effectively managed by revision to a rTSA

(3) The salvage pathway for patients with rTSA failure is poor. Revision rTSA carries a 31% complication rate and 27% re-revision rate, with outcomes that are significantly worse than those for primary rTSA. This contrasts sharply with aTSA-to-rTSA conversion, the outcome of which approaches the outcomes for primary rTSA. 

The details

Complications vs revisions

Meta-analytic evidence reports that anatomic total shoulder (aTSA) has a higher rate of revision compared to reverse total shoulder (rTSA). This observation may have driven much of the shift toward rTSA for patients with cuff-intact arthritis.  However, it may neglect the fact that surgeons and patients can decide against revision of a failed rTSA because of the low rate of success. Thus, the absence of a revision does not indicate a good outcome.

Consider the references below

Complications and further surgery after reverse total shoulder arthroplasty : report of 854 primary cases reported an overall complication rate of 18–22%, yet a revision rate of only ~10%. That 8–12 percentage point gap likely represents 
patients who are living with a failing implant — either because revision was technically not feasible, or because expected outcomes were too poor to justify reoperation

Incidence, radiographic predictors, and clinical outcome of acromial stress reaction and acromial fractures in reverse total shoulder arthroplasty found 46 acromial stress fractures (5.4%) in 44 patients and 44 acromial stress reactions (5.2%) in 43 patients. The overall union rate was 55% but was significantly higher following operative treatment compared with nonoperative treatment. However, facture consolidation did not result in better clinical outcomes compared with nonunion; this may question the value of attempted fixation.

Comparison of complication types and rates associated with anatomic and reverse total shoulder arthroplasty found that the top 3 complications for rTSA were acromial/scapular fracture/pain ( complication rate 2.5%, revision rate 0.0%), instability (complication rate 1.4%, revision rate 1.0%), pain (1.2%, revision rate 0.2%). 
Compare the relationship of complications to revisions for rTSA to that for aTSA in the two charts below constructed from the data in this article. Note that a high percentage of the rTSA complications were not associated with surgical revision. Absence of revision ≠ absence of complication,












The Gap Between Revision-Free and Complication-Free Survival 

Long-Term Outcomes of Reverse Total Shoulder Arthroplasty
A Follow-up of a Previous Study The 93% ten-year revision-free survival rate for rTSA did not capture the 29% of patients who experienced complications.

Long term clinical and radiological outcomes of primary reverse total shoulder arthroplasty at a minimum follow-up of 15 years: Norwegian registry data showed 10-year complication-free rates of only 76–80%, despite revision-free survival of 91–95%. That 15–20 percentage point gap represents patients living with failed implants who are invisible in the revision statistics. Again, this gap exists because many rTSA complications—particularly acromial fractures, low-grade infection, and baseplate loosening with severe bone loss—either cannot be addressed surgically or carry such poor expected revision outcomes that conservative management is chosen.

Revision rates alone remain an inadequate measure of rTSA performance; complication-free survival is the more appropriate endpoint.


Outcomes of Revision rTSA

Revision of reverse total shoulder arthroplasty: a scoping review of indications for revision, and revision outcomes, complications, and rerevisions and Revision of failed shoulder arthroplasty: epidemiology, etiology, and surgical options found the most common indications for revision to be instability/dislocation (28–30%), baseplate or glenoid complications (20–25%), and infection (15–23%). Notably low on the list is revision for the most common complication: acromial/spine fractures.

Outcomes After Revision
Revision reverse total shoulder arthroplasty: clinical and radiographic outcomes compared to primary reverse total shoulder arthroplasty found a 31% complication rate and 27% re-revision rate of a failed rTSA: over five times these rates after primary rTSA. The most common complications after revision are recurrent instability (22%), fractures (18%), and baseplate issues (12%). Patients requiring revision rTSA experience markedly worse comfort and function in comparison to primary rTSA

The Salvage Pathway Asymmetry:  revision for aTSA Failure compared to revision for rTSA Failure

Summary: Three takeaway points (again)

(1) The commonly used and easy to measure "revision rate" is an inadequate endpoint for evaluating rTSA outcomes. The 8–20 percentage point gap that exists between the complication rate and the revision rate includes a substantial number of patients with failed but unrevised reverse shoulder arthroplasties. These patients are not considered in determining the failure rate when measured by the percentage having revision. Complication-free survival or patient-reported outcome measures should supplement or replace revision rate or "implant survival" as the primary outcome measure for rTSA.

(2) The most common complications of rTSA, acromial and scapular spine fractures, are unique and difficult to solve problems for patients having reverse arthroplasty. In contrast, the most common complications from aTSA - glenoid component loosening and rotator cuff tear - can be effectively managed by revision to a rTSA

(3) The salvage pathway for patients with rTSA failure is poor. Revision rTSA carries a 31% complication rate and 27% re-revision rate, with outcomes that are significantly worse than those for primary rTSA. This contrasts sharply with aTSA-to-rTSA conversion, the outcome of which approaches the outcomes for primary rTSA. 


Swans reversing course

Trumpeter Swans
Union Bay Natural Area
Seattle








Friday, October 31, 2025

Does glenoid component version correlate with clinical outcome in aTSA?

Preoperarive glenoid retroversion is common in shoulders having anatomic total shoulder arthroplasty (aTSA). 


Some surgeons contend that - when performing aTSA - it is important to insert the glenoid component in 15 degrees or less retroversion. This is accomplished by eccentric reaming of the anterior glenoid bone, use of a posteriorly augmented glenoid component, or both. As shown below, this approach can come at the cost of removing robust glenoid bone,


An alternative approach is to preserve glenoid bone stock by accepting (rather than correcting) glenoid retroversion (shown in the lower half of the figure below),


And in this set of x-rays obtained 10 years after surgery

The authors of Does postoperative glenoid component retroversion following anatomic total shoulder arthroplasty affect clinical outcomes? A systematic review and meta-analysis reviewed the available evidence relating patient reported outcomes to the retroversion in which an anatomic glenoid component was inserted.  Fifteen articles (1,190 shoulders) reporting postoperative clinical outcomes and measurements of glenoid component version after primary anatomic shoulder arthroplasty were identified and submitted for meta-analysis. Patients were divided into 2 groups based on postoperative glenoid component retroversion: (a) < 15° and (b) ≥ 15°. When comparing patient reported outcome scores, range of motion, and complications for shoulders with <15 or ≥15 degrees of glenoid component retroversion, no clinically significant differences were noted between the 2 groups at a mean followup of 51 months. Specifically, the ASES scores, range of motion, complication rates, and revision rates were essentially identical. Shoulders with ≥15 degrees of retroversion had less radiolucency. Corrective (eccentric) reaming was associated with higher complication and revision rates.


Several other recent articles support these findings:

Does glenoid version and its correction affect outcomes in anatomic shoulder arthroplasty? A systematic review "There is currently insufficient evidence that pre- or postoperative glenoid version influences postoperative outcomes independent of other morphologic factors such as joint line medialization. Given that noncorrective reaming demonstrated favorable postoperative outcomes, and postoperative glenoid version was not significantly and consistently found to impact outcomes, there is inconclusive evidence that correcting glenoid retroversion is routinely required."

Anatomic total shoulder arthroplasty for posteriorly eccentric and concentric osteoarthritis: a comparison at a minimum 5-year follow-up "At a mean 8-year follow-up, the final SST score, change in SST score, and percentage of maximal improvement was not correlated with pre- and postoperative humeral head centering, Walch classification, or glenoid version." "Incomplete glenoid component seating was the greatest predictor of glenoid component radiolucency"
 
Glenoid retroversion does not impact clinical outcomes or implant survivorship after total shoulder arthroplasty with minimal, noncorrective reaming "Anatomic total shoulder replacement with minimal and noncorrective glenoid reaming demonstrates reliable increases in patient satisfaction and clinical outcomes at a mean of 4.6-year follow-up in patients with up to 40° of native retroversion. Higher values of retroversion were not associated with early deterioration of clinical outcomes, revisions, or failures."

Comment:
Substantial resources are being directed at measuring, planning for, and correcting preoperative glenoid retroversion when performing anatomic total shoulder arthroplasty. These recent studies question whether these efforts are of value to the patient when treating arthritic retroversion with aTSA.

What is the best orientation?

Red-tailed hawks in combat
Union Bay Natural Area
Oct 2021

Follow on twitter/X: https://x.com/RickMatsen
Follow on facebook: https://www.facebook.com/shoulder.arthritis
Follow on LinkedIn: https://www.linkedin.com/in/rick-matsen-88b1a8133/

Here are some videos that are of shoulder interest
Shoulder arthritis - what you need to know (see this link).
How to x-ray the shoulder (see this link).
The ream and run procedure (see this link)
The total shoulder arthroplasty (see this link)
The cuff tear arthropathy arthroplasty (see this link).
The reverse total shoulder arthroplasty (see this link).
The smooth and move procedure for irreparable rotator cuff tears (see this link)
Shoulder rehabilitation exercises (see this link).